Science
New formulation helps RNA vaccines withstand high temperatures
Publication: Phys.org - latest science and technology news stories
Author: Not available in collected metadata
Source published: 28/09/2026, 09:00:01 UTC
Briefing created: 28/09/2026, 09:13:54 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 28/09/2026, 09:10:24 UTC.
Briefings
MIT researchers developed a new formulation enabling RNA vaccines to withstand high temperatures, addressing a key limitation for expanding vaccine applications beyond COVID-19. The study, published in September 2026, suggests this advancement could support broader disease coverage while maintaining immunological efficacy.
Key points
- MIT researchers successfully formulated an RNA vaccine that can survive elevated temperatures, overcoming the requirement for ultracold storage previously needed for many vaccines.
- The study was published in September 2026, marking a significant step toward making RNA vaccines viable for diverse disease targets like cancer.
Context and limitations
The evidence is limited to a single study from September 2026; long-term stability data beyond the initial formulation period remains unconfirmed.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 28/09/2026, 09:13:54 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeihjns3qk4x7zvia3rgho244hmqebyohfvpsy4fwrmcpfhpcedf3se